1. Home
  2. News
  3. Neuren Pharmaceuticals Limited
  4. Acadia submits Rett Syndrome New Drug Application to the FDA
More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

Acadia submits Rett Syndrome New Drug Application to the FDA

Jul 19, 2022 at 12:07 AM EDT · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Jul 19, 2022 at 12:07 AM EDT · 5 pages · English

On 6ix: 6ix.com/news/acadia-submits-rett-syndrome-new-drug-application-to-the-fda

Neuren Pharmaceuticals Limited on 6ix

Story so far

  • Positive topline results from Phase 3 trial in Rett syndromeDec 7, 2021
  • Update on trofinetide Phase 3 trial in Rett syndromeFeb 19, 2020
  • Phase 3 trial of trofinetide in Rett syndrome commencesOct 31, 2019

Earlier from Neuren Pharmaceuticals

  • Neuren commences Phase 2 trial of NNZ-2591 in AngelmanJul 11, 2022
  • Neuren appoints Chief Medical Officer in United StatesJul 8, 2022
  • FDA approval for Pitt Hopkins syndrome IND and Phase 2 trialMar 24, 2022
  • FDA approval for Phelan-McDermid IND and Phase 2 trialMar 22, 2022
  • Ethics approval for Angelman Phase 2 trial in AustraliaMar 10, 2022

Later from Neuren Pharmaceuticals

  • Quarterly Activities/Appendix 4C Cash Flow ReportJul 29, 2022
  • Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHSAug 7, 2022
  • S&P DJI Announces September 2022 Quarterly RebalanceSep 2, 2022
  • Rett Syndrome NDA accepted for Priority Review by FDASep 12, 2022
  • Neuren receives US$10 million milestone paymentOct 19, 2022
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer